Unveiling the Potential of Prostate-Specific Membrane Antigen for Precision Diagnosis and Therapy of Prostate Cancer: A Radiopharmaceutical Perspective.

IF 1.1 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

Malaysian Journal of Medical Sciences Pub Date : 2024-08-01 Epub Date: 2024-08-27 DOI:10.21315/mjms2024.31.4.17

Hishar Hassan, Muhamad Faiz Othman, Zarif Naim Ashhar, Hairil Rashmizal Abdul Razak, Fathinul Fikri Ahmad Saad

{"title":"Unveiling the Potential of Prostate-Specific Membrane Antigen for Precision Diagnosis and Therapy of Prostate Cancer: A Radiopharmaceutical Perspective.","authors":"Hishar Hassan, Muhamad Faiz Othman, Zarif Naim Ashhar, Hairil Rashmizal Abdul Razak, Fathinul Fikri Ahmad Saad","doi":"10.21315/mjms2024.31.4.17","DOIUrl":null,"url":null,"abstract":"Prostate-specific membrane antigen (PSMA) has proven to be an important target for diagnostic imaging in prostate cancer. As PSMA is overexpressed on the surface of prostate cancer cells, numerous targeted PSMA ligands have been developed. The emergence of PSMA targeting based on small molecules, such as the PSMA-11 ligand (or PSMA-HBED-CC), has led to breakthroughs, such as [68Ga]Ga-PSMA-11, for positron emission tomography (PET) imaging of biochemically recurrent or metastatic castration-resistant prostate cancer (mCRPC). In addition, the recent approval of [177Lu]Lu-PSMA-617 for the treatment of adult patients with PSMA-positive mCRPC represents an important milestone in prostate cancer therapy. These advances underscore the growing confidence in the use of PSMA-targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer patients. PSMA-targeted radiopharmaceuticals have been shown to significantly impact treatment planning and clinical decision-making and facilitate the customisation of treatment regimens.","PeriodicalId":47388,"journal":{"name":"Malaysian Journal of Medical Sciences","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377010/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Malaysian Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21315/mjms2024.31.4.17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Prostate-specific membrane antigen (PSMA) has proven to be an important target for diagnostic imaging in prostate cancer. As PSMA is overexpressed on the surface of prostate cancer cells, numerous targeted PSMA ligands have been developed. The emergence of PSMA targeting based on small molecules, such as the PSMA-11 ligand (or PSMA-HBED-CC), has led to breakthroughs, such as [⁶⁸Ga]Ga-PSMA-11, for positron emission tomography (PET) imaging of biochemically recurrent or metastatic castration-resistant prostate cancer (mCRPC). In addition, the recent approval of [¹⁷⁷Lu]Lu-PSMA-617 for the treatment of adult patients with PSMA-positive mCRPC represents an important milestone in prostate cancer therapy. These advances underscore the growing confidence in the use of PSMA-targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer patients. PSMA-targeted radiopharmaceuticals have been shown to significantly impact treatment planning and clinical decision-making and facilitate the customisation of treatment regimens.

查看原文本刊更多论文

揭示前列腺特异性膜抗原在前列腺癌精准诊断和治疗中的潜力：放射性药物视角。

前列腺特异性膜抗原（PSMA）已被证明是前列腺癌诊断成像的一个重要靶点。由于 PSMA 在前列腺癌细胞表面过度表达，因此开发了许多 PSMA 靶向配体。以 PSMA-11 配体（或 PSMA-HBED-CC）等小分子为基础的 PSMA 靶向技术的出现带来了突破性进展，如 [68Ga]Ga-PSMA-11 可用于生化复发性或转移性去势抵抗性前列腺癌（mCRPC）的正电子发射断层扫描（PET）成像。此外，[177Lu]Lu-PSMA-617 最近被批准用于治疗 PSMA 阳性的 mCRPC 成年患者，这是前列腺癌治疗领域的一个重要里程碑。这些进展凸显了人们对使用 PSMA 靶向放射性药物诊断和治疗前列腺癌患者的信心与日俱增。事实证明，PSMA靶向放射性药物对治疗计划和临床决策有显著影响，并有助于定制治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Malaysian Journal of Medical Sciences MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

2.70

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： The Malaysian Journal of Medical Sciences (MJMS) is a peer-reviewed, open-access, fully online journal that is published at least six times a year. The journal’s scope encompasses all aspects of medical sciences including biomedical, allied health, clinical and social sciences. We accept high quality papers from basic to translational research especially from low & middle income countries, as classified by the United Nations & World Bank (https://datahelpdesk.worldbank.org/knowledgebase/ articles/906519), with the aim that published research will benefit back the bottom billion population from these countries. Manuscripts submitted from developed or high income countries to MJMS must contain data and information that will benefit the socio-health and bio-medical sciences of these low and middle income countries. The MJMS editorial board consists of internationally regarded clinicians and scientists from low and middle income countries.